Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 1197023014 | Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 1210334010 | Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | est un(e) (attribut) | Metronidazole-containing product in oral dose form | false | Inferred relationship | Some | ||
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | est un(e) (attribut) | Product containing tetracycline in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | a pour principe actif (attribut) | Metronidazole (substance) | false | Inferred relationship | Some | ||
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | a pour principe actif (attribut) | Tetracycline (substance) | false | Inferred relationship | Some | ||
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | est un(e) (attribut) | Product containing bismuth subsalicylate and metronidazole and tetracycline (medicinal product) | false | Inferred relationship | Some | ||
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | a pour principe actif (attribut) | Bismuth | false | Inferred relationship | Some | ||
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | a pour principe actif (attribut) | Bismuth subsalicylate | false | Inferred relationship | Some | ||
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | a pour principe actif (attribut) | Antacid (substance) | false | Inferred relationship | Some | ||
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | a pour principe actif (attribut) | Bactericide | false | Inferred relationship | Some | ||
| Bismuth subsalicylate+metronidazole+tetracycline hydrochloride 262.4 mg/250 mg/500 mg kit (product) | a une forme pharmaceutique (attribut) | forme orale | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Concept inactivation indicator reference set
FHIR